NCT01995240

Functional Magnetic Resonance Imaging of Pancreatic Cancer: a Feasibility and Reproducibility Study

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 23 (actual)
• Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Novel predictive markers are needed to determine treatment efficacy in pancreatic cancer at an early stage. Preferably, these markers could be determined non-invasively and provide insight into the biology of pancreatic cancer. Several MR techniques can serve for this purpose. However, optimalisation of these techniques is needed and their reproducibility should be assessed.

Detailed description

Background of the study: Novel predictive markers are needed to determine treatment efficacy in pancreatic cancer at an early stage. Preferably, these markers could be determined non-invasively and provide insight into the biology of pancreatic cancer. Several MR techniques can serve for this purpose. However, optimalisation of these techniques is needed and their reproducibility should be assessed. Objective of the study: To optimize DCE-MRI, T2\* MRI and DWI in pancreatic cancer at 3T and investigate its reproducibility. Study design: In the first part of the study, patients with pancreatic cancer will undergo an MR measurement protocol once at 3T, to optimize MR techniques (DCE-MRI, T2\* MRI and DWI). In the second part of the study, to assess reproducibility patients will undergo the MR measurement protocol twice within one week before start of any treatment.

Conditions

• Pancreatic Cancer

Interventions

Type	Name	Description
DRUG	Gadobutrol	0.1 ml/kg Gadovist is administered at 5 ml/s followed by a 15 ml saline flush

Timeline

• Start date: 2013-04-01
• Primary completion: 2017-02-01
• Completion: 2017-02-01
• First posted: 2013-11-26
• Last updated: 2017-03-20

Locations

1 site across 1 country: Netherlands